Clopidogrel Teva Pharma B.V.

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
03-02-2015
Summary of Product characteristics Summary of Product characteristics (SPC)
03-02-2015
Public Assessment Report Public Assessment Report (PAR)
03-02-2015

Active ingredient:

clopidogrel (as hydrobromide)

Available from:

Teva Pharma B.V. 

ATC code:

B01AC04

INN (International Name):

clopidogrel

Therapeutic group:

Antithrombotic agents

Therapeutic area:

Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke

Therapeutic indications:

Prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome: non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.

Product summary:

Revision: 4

Authorization status:

Withdrawn

Authorization date:

2011-06-16

Patient Information leaflet

                                B. PACKAGE LEAFLET
32
Medicinal product no longer authorised
PACKAGE LEAFLET: INFORMATION FOR THE USER
CLOPIDOGREL TEVA PHARMA B.V. 75 MG FILM-COATED TABLETS
clopidogrel
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you have any side effects, including any side effects not listed in
this leaflet, talk your doctor
or pharmacist. See section 4
WHAT IS IN THIS LEAFLET
1.
What Clopidogrel Teva Pharma B.V. is and what it is used for
2.
What you need to know before you take Clopidogrel Teva Pharma B.V.
3.
How to take Clopidogrel Teva Pharma B.V.
4.
Possible side effects
5.
How to store Clopidogrel Teva Pharma B.V.
6.
Contents of the pack and other information
1. WHAT CLOPIDOGREL TEVA PHARMA B.V. IS AND WHAT IT IS USED FOR
Clopidogrel Teva Pharma B.V contains clopidogrel and belongs to a
group of medicines called
“platelet aggregation inhibitors.” It works by stopping certain
particles in your blood (“platelets”)
from sticking together to form blood clots which can block blood flow
to important parts of your body
including your heart and your brain.
If you suffer from hardening of the arteries (“atherosclerosis”)
there is an increased risk of a blood clot
forming in your blood vessels. In adults Clopidogrel Teva Pharma B.V.
reduces the risk of blood clots
forming which in turn reduces the risk of serious conditions such as
heart attack and stroke from
occurring.
You have been prescribed Clopidogrel Teva Pharma B.V. because:
•
You have hardening of the arteries and have recently suffered from a
heart attack, a stroke or
have a condition known as “peripheral arterial disease” (diseases
of the blood vessels except
those in the brain and heart).
•
You have 
                                
                                Read the complete document

Summary of Product characteristics

                                ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1
Medicinal product no longer authorised
1.
NAME OF THE MEDICINAL PRODUCT
Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 75 mg of clopidogrel (as
hydrobromide).
Excipients with known effect:
Each tablet contains 62.16 mg lactose monohydrate and 10 mg
hydrogenated castor oil.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Light pink to pink, capsule-shaped film-coated tablets debossed with
“C75” on one side and plain on
the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
_Prevention of atherothrombotic events _
Clopidogrel is indicated in:
•
Adult patients suffering from myocardial infarction (from a few days
until less than 35 days),
ischaemic stroke (from 7 days until less than 6 months) or established
peripheral arterial disease.
•
Adult patients suffering from acute coronary syndrome:
-
Non-ST segment elevation acute coronary syndrome (unstable angina or
non-Q-wave
myocardial infarction), including patients undergoing a stent
placement following
percutaneous coronary intervention, in combination with
acetylsalicylic acid (ASA)
-
ST segment elevation acute myocardial infarction, in combination with
ASA in medically
treated patients eligible for thrombolytic therapy.
_Prevention of atherothrombotic and thromboembolic events in atrial
fibrillation _
In adult patients with atrial fibrillation who have at least one risk
factor for vascular events, are not
suitable for treatment with Vitamin K antagonists (VKA) and who have a
low bleeding risk,
clopidogrel is indicated in combination with ASA for the prevention of
atherothrombotic and
thromboembolic events, including stroke.
For further information please refer to section 5.1.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology:
•
Adults and older people
Clopidogrel should be given as a single daily dose of 75 mg.
2
Medicinal product no longer authorised
In patients suff
                                
                                Read the complete document

Similar products

Active ingredient clopidogrel (as hydrobromide)

clopidogrel (as hydrobromide)

ATC code B01AC04

B01AC04

Marketed by Teva Pharma B.V. 

Teva Pharma B.V. 

INN (International Name) clopidogrel

clopidogrel

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 03-02-2015
Summary of Product characteristics Summary of Product characteristics Bulgarian 03-02-2015
Public Assessment Report Public Assessment Report Bulgarian 03-02-2015
Patient Information leaflet Patient Information leaflet Spanish 03-02-2015
Summary of Product characteristics Summary of Product characteristics Spanish 03-02-2015
Public Assessment Report Public Assessment Report Spanish 03-02-2015
Patient Information leaflet Patient Information leaflet Czech 03-02-2015
Summary of Product characteristics Summary of Product characteristics Czech 03-02-2015
Public Assessment Report Public Assessment Report Czech 03-02-2015
Patient Information leaflet Patient Information leaflet Danish 03-02-2015
Summary of Product characteristics Summary of Product characteristics Danish 03-02-2015
Public Assessment Report Public Assessment Report Danish 03-02-2015
Patient Information leaflet Patient Information leaflet German 03-02-2015
Summary of Product characteristics Summary of Product characteristics German 03-02-2015
Public Assessment Report Public Assessment Report German 03-02-2015
Patient Information leaflet Patient Information leaflet Estonian 03-02-2015
Summary of Product characteristics Summary of Product characteristics Estonian 03-02-2015
Public Assessment Report Public Assessment Report Estonian 03-02-2015
Patient Information leaflet Patient Information leaflet Greek 03-02-2015
Summary of Product characteristics Summary of Product characteristics Greek 03-02-2015
Public Assessment Report Public Assessment Report Greek 03-02-2015
Patient Information leaflet Patient Information leaflet French 03-02-2015
Summary of Product characteristics Summary of Product characteristics French 03-02-2015
Public Assessment Report Public Assessment Report French 03-02-2015
Patient Information leaflet Patient Information leaflet Italian 03-02-2015
Summary of Product characteristics Summary of Product characteristics Italian 03-02-2015
Public Assessment Report Public Assessment Report Italian 03-02-2015
Patient Information leaflet Patient Information leaflet Latvian 03-02-2015
Summary of Product characteristics Summary of Product characteristics Latvian 03-02-2015
Public Assessment Report Public Assessment Report Latvian 03-02-2015
Patient Information leaflet Patient Information leaflet Lithuanian 03-02-2015
Summary of Product characteristics Summary of Product characteristics Lithuanian 03-02-2015
Public Assessment Report Public Assessment Report Lithuanian 03-02-2015
Patient Information leaflet Patient Information leaflet Hungarian 03-02-2015
Summary of Product characteristics Summary of Product characteristics Hungarian 03-02-2015
Public Assessment Report Public Assessment Report Hungarian 03-02-2015
Patient Information leaflet Patient Information leaflet Maltese 03-02-2015
Summary of Product characteristics Summary of Product characteristics Maltese 03-02-2015
Public Assessment Report Public Assessment Report Maltese 03-02-2015
Patient Information leaflet Patient Information leaflet Dutch 03-02-2015
Summary of Product characteristics Summary of Product characteristics Dutch 03-02-2015
Public Assessment Report Public Assessment Report Dutch 03-02-2015
Patient Information leaflet Patient Information leaflet Polish 03-02-2015
Summary of Product characteristics Summary of Product characteristics Polish 03-02-2015
Public Assessment Report Public Assessment Report Polish 03-02-2015
Patient Information leaflet Patient Information leaflet Portuguese 03-02-2015
Summary of Product characteristics Summary of Product characteristics Portuguese 03-02-2015
Public Assessment Report Public Assessment Report Portuguese 03-02-2015
Patient Information leaflet Patient Information leaflet Romanian 03-02-2015
Summary of Product characteristics Summary of Product characteristics Romanian 03-02-2015
Public Assessment Report Public Assessment Report Romanian 03-02-2015
Patient Information leaflet Patient Information leaflet Slovak 03-02-2015
Summary of Product characteristics Summary of Product characteristics Slovak 03-02-2015
Public Assessment Report Public Assessment Report Slovak 03-02-2015
Patient Information leaflet Patient Information leaflet Slovenian 03-02-2015
Summary of Product characteristics Summary of Product characteristics Slovenian 03-02-2015
Public Assessment Report Public Assessment Report Slovenian 03-02-2015
Patient Information leaflet Patient Information leaflet Finnish 03-02-2015
Summary of Product characteristics Summary of Product characteristics Finnish 03-02-2015
Public Assessment Report Public Assessment Report Finnish 03-02-2015
Patient Information leaflet Patient Information leaflet Swedish 03-02-2015
Summary of Product characteristics Summary of Product characteristics Swedish 03-02-2015
Public Assessment Report Public Assessment Report Swedish 03-02-2015
Patient Information leaflet Patient Information leaflet Norwegian 03-02-2015
Summary of Product characteristics Summary of Product characteristics Norwegian 03-02-2015
Patient Information leaflet Patient Information leaflet Icelandic 03-02-2015
Summary of Product characteristics Summary of Product characteristics Icelandic 03-02-2015
Patient Information leaflet Patient Information leaflet Croatian 03-02-2015
Summary of Product characteristics Summary of Product characteristics Croatian 03-02-2015

Search alerts related to this product

Alerts Clopidogrel Teva Pharma B.V.

Clopidogrel Teva Pharma B.V.

View documents history

Documents history Documents history

Clopidogrel Teva Pharma B.V.